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Background: Microtubule associated protein tau is the major component of the neurofibrillary tangles (NFTs)
found in the brains of patients with Alzheimer’s disease and several other neurodegenerative diseases. Tau
mutations are associated with frontotemperal dementia with parkinsonism on chromosome 17 (FTDP-17). rTg4510
mice overexpress human tau carrying the P301L FTDP-17 mutation and develop robust NFT-like pathology at 4–5
months of age. The current study is aimed at characterizing the rTg4510 mice to better understand the genesis of
tau pathology and to better enable the use of this model in drug discovery efforts targeting tau pathology.
Results: Using a panel of immunoassays, we analyzed the age-dependent formation of pathological tau in rTg4510 mice
and our data revealed a steady age-dependent accumulation of pathological tau in the insoluble fraction of brain
homogenates. The pathological tau was associated with multiple post-translational modifications including aggregation,
phosphorylation at a wide variety of sites, acetylation, ubiquitination and nitration. The change of most tau species
reached statistical significance at the age of 16 weeks. There was a strong correlation between the different
post-translationally modified tau species in this heterogeneous pool of pathological tau. Total tau in the cerebrospinal
fluid (CSF) displayed a multiphasic temporal profile distinct from the steady accumulation of pathological tau in the brain.
Female rTg4510 mice displayed significantly more aggressive accumulation of pathological tau in the brain and elevation
of total tau in CSF than their male littermates.
Conclusion: The immunoassays described here were used to generate the most comprehensive description of the
changes in various tau species across the lifespan of the rTg4510 mouse model. The data indicate that development of
tauopathy in rTg4510 mice involves the accumulation of a pool of pathological tau that carries multiple post-
translational modifications, a process that can be detected well before the histological detection of NFTs. Therapeutic
treatment targeting tau should therefore aim to reduce all tau species associated with the pathological tau pool rather
than reduce specific post-translational modifications. There is still much to learn about CSF tau in physiological and
pathological processes in order to use it as a translational biomarker in drug discovery.
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Microtubule associated protein tau is expressed primar-
ily in neurons and plays an important role in axonal
transport [1]. Abnormal accumulation of tau in the brain
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unless otherwise stated.formation of neurofibrillary tangles (NFTs), which to-
gether with β-amyloid plaques are the two pathological
hallmarks of the disease [2,3]. While plaques can be
found in post-mortem brains from people without sig-
nificant clinical AD symptoms, the presence of NFTs
correlates well with neuronal cell death and the loss of
cognitive functions. In addition, NFTs are also found in
the brains of patients with several other neurodegenera-
tive diseases that lack amyloid pathology [2]. Under-
standing the development of tau pathology, also known
as tauopathy, should provide important insights into thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and into the development of therapeutic strategies tar-
geting this pathway.
Human tau exists as six alternatively spliced isoforms, with
its C-terminal half containing either 3 or 4 repeats of the
microtubule binding domain (designated as either 3R or 4R
tau). In adult brain under normal physiological conditions,
the 3R and 4R tau are present in about a 1:1 ratio. Patho-
logical tau in AD brain is hyperphosphorylated and forms in-
soluble aggregates that eventually develop into NFTs [2].
This observation has led to the hypothesis that abnormal
phosphorylation plays a major role in the disease process. In
addition to phosphorylation, tau undergoes multiple post-
translational modifications such as acetylation, nitration, ubi-
quitination, etc. [4,5]. Moreover, tau is also present in cere-
bral spinal fluid (CSF) and tau in CSF is elevated in AD
patients long before the clinical symptoms of the disease are
manifest [6]. These findings suggest that the development of
tauopathy is dependent on far more than just hyperpho-
sphorylation. The biological and pathological processes in-
volved in tau post-translational modifications and CSF tau
production are largely unknown.
The identification of tau mutations associated with fronto-
temporal dementia with parkinsonism on chromosome 17
(FTDP-17) [7,8] establishes the pathogenic role of tau in me-
diating neurodegeneration and cognitive decline. FTDP-17
mutations affect the tau microtubule binding or alternative
splicing in favor of the 4R form of tau (reviewed by [1]).
Many transgenic animal models have been generated to ex-
plore the mechanism of tauopathy development. Transgenic
models expressing human tau with missense FTDP-17 muta-
tions display more robust NFT formation compared to those
that express wild-type human tau [9]. One of the models, the
rTg4510 mouse, overexpresses a human tau transgene carry-
ing a P301L mutation, with transgene expression driven by
the Ca2+-calmodulin kinase II promoter [10]. NFT staining
can be detected in rTg4510 mice as early as 5–6 months of
age and, like NFT pathology in AD, is restricted to the fore-
brain structures such as hippocampus and cortex. This
model also develops neuronal cell loss, brain atrophy and
cognitive decline reminiscent of that seen in AD patients
[10,11], making it an attractive model to investigate disease
mechanisms and test potential therapeutic agents.
Here we report the development of a comprehensive
panel of sandwich immunoassays to study the tauopathy in
rTg4510 mice. The sensitivity and quantitative nature of
these assays enabled us to investigate the correlations be-
tween different tau species over the lifespan of the rTg4510
mice, thereby providing important information on the
properties of pathological tau and the time course of its de-
velopment in this model. These findings will guide the ef-
fective use of rTg4510 mice in studies of the basic biology
of AD and other tauopathies, and in the assessment of po-
tential treatments for these conditions.Results
To study changes in tau during disease progression in
rTg4510 mice, we separated the brain homogenates into
soluble and insoluble fractions by a simple two step centri-
fugation process based on a previously reported study [12].
Western blots probed with HT7 and tau-12 antibodies,
which recognize epitopes independent of phosphorylation
and detect total tau, revealed an age-dependent decrease of
total tau in the soluble fraction and an age-dependent in-
crease of total tau in the insoluble fraction. Tau in the in-
soluble fraction also underwent a transition from a 55 kD
species to a higher molecular weight 64 kD species as the
animals aged (Figure 1A). There were two distinct profiles
of phosphorylated tau (p-tau) changes during disease pro-
gression in the rTg4510 mice. One type of p-tau, as de-
tected by antibodies AT8, PHF6, AT180, PHF13 and
pS409, was enriched in the 64 kD form in the insoluble
fraction and increased in the insoluble fraction as the ani-
mals aged (Figure 1B). The second type of p-tau, as de-
tected by antibodies AT270, pS400, pS404 and pS412,
displayed a profile similar to that of total tau, i.e., a de-
crease in the soluble fraction, an increase in the insoluble
fraction and a transition from a 55 kD to a 64 kD species
in the insoluble fraction as the animals aged (Figure 1C).
These data are consistent with observations from other
groups and demonstrate an age-dependent development
and accumulation of a 64 kD species of pathological tau
that is enriched in the insoluble fraction of brain extracts
and correlates with the development of tauopathy, neur-
onal cell loss, brain atrophy and cognitive impairment [10].
Next we focused on the change of tau in the insoluble
fraction in which the pathological 64 kD tau species was
enriched. A panel of sensitive sandwich immunoassays was
developed using AlphaLISA technology (PerkinElmer) to
analyze different tau species during the progression of tauo-
pathy in rTg4510 mice (Table 1). An age-dependent accu-
mulation of both total tau and aggregated tau was observed
in the insoluble fraction (Figure 2A and 2B). It is noteworthy
that large inter-animal variations in both total and aggre-
gated tau were observed within each age group, particularly
at older ages where tauopathy was progressing rapidly and
significant amounts of tau were accumulating in the insol-
uble fraction. The various species of p-tau studied also
showed an age-dependent increase in the insoluble fraction,
including p-tau species detected by PHF6 (conformation
around pT231; Figure 3A), AT8 (pS202/T205; Figure 3B),
pS262, pS400, AT180 (pT231), PHF13 (pS396), AT100
(pS212/pT214) and pS409 (Additional file 1: Figure S1). We
also developed an immunoassay for global tau phosphoryl-
ation using a pan anti-phosphothreonine antibody and
showed that, similar to other p-tau species, pThr global tau
phosphorylation was also elevated in the insoluble fraction
(Figure 3C). For most of the tau species in the soluble
fraction, the age-dependent increase reached statistical
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Figure 1 Western blot analysis of various tau species in brain lysates from Tg4510 mice of different ages. Soluble and insoluble fractions
of brain homogenates were prepared as described in Methods from rTg4510 mice that were 6, 16 or 32 weeks of age. Ten μg of protein from
each fraction was analyzed by probing Western blots with the specified antibodies. The position of the 55 kD and 64 kD species of tau are
indicated. α-Tubulin was used as a loading control. A. Total tau detected by two different antibodies (HT7 and Tau12). B. P-tau species enriched
in 64 kD tau in the insoluble fraction. C. P-tau species present in both the 55 kD species in the soluble fraction and in the 64 kD species in the
insoluble fraction.
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(one-way ANOVA, p < 0.05, Figures 2 and 3, Additional file
1: Figure S1).
A further analysis revealed that despite the large varia-
tions between animals, the levels of all p-tau species showed
strong correlation with the levels of the p-tau species
recognized by PHF6, including AT8 (R2 = 0.9, p < 0.0001,
Figure 4A), pThr global phosphorylation (R2 = 0.89,
p < 0.0001, Figure 4B), pS262 (R2 = 0.82, p < 0.0001), pS400
(R2 = 0.88, p < 0.0001), AT180 (R2 = 0.93, p < 0.0001),
PHF13 (R2 = 0.9, p < 0.0001), AT100 (R2 = 0.94, p < 0.0001)
and pS409 ((R2 = 0.8, p < 0.0001, Additional file 2: Figure S2).
In addition, a significant correlation was observed between
PHF6 tau and tau aggregates (R2 = 0.80, p < 0.0001,
Figure 4C) and between PHF6 tau and total tau (R2 = 0.69,
p < 0.0001, Figure 4D) in the insoluble fraction.
Tau acetylation has recently been reported to be in-
creased in the brains of tau transgenic mice and in the
brains of AD patients [13,14]. Western blots probed with
Ac-280 showed this tau species acetylated at Lys280
migrated with the 55 kD tau species in the soluble frac-
tion from young rTg4510 mice but shifted to the 64 kD
species in the insoluble fraction as tauopathy progressed
(Figure 5A). An immunoassay to assess global tau acetyl-
ation was developed that utilized a pan anti-acetylatedlysine antibody in combination with antibody HT7. This
immunoassay confirmed that the global tau acetylation
was much enriched in the insoluble fraction as com-
pared to the soluble fraction. The acetylated tau was ele-
vated as the rTg4510 animals aged and the change reached
statistical significance at the age of 14-weeks as compared
to 8-weeks (p < 0.05, one-way ANOVA, Figure 5B). Inter-
estingly, acetylated tau also showed a strong correlation
with PHF6 tau in the insoluble fraction (R2 = 0.76, p <
0.0001, Figure 5C), suggesting that both modifications are
present in the same pool of tau that contribute to tauopathy
and neurodegeneration in this model.
Next we examined ubiquitination and tyrosine nitration of
tau in rTg4510 mice, both of which have also been shown to
be associated with NFT pathology [15-17]. As seen with
multiple p-tau species and acetylated tau, both ubiquitinated
tau (ub-tau) and tau nitrated at tyrosine 29 (nY29 tau) were
enriched in the insoluble fraction and showed age-
dependent increases in rTg4510 mice (Figure 6A and B).
We did not detect either ub-tau or nY29 tau in the soluble
fraction using the assays described here (data not shown).
Compared to 8-week old mice, the changes of ub-tau and
nY29 tau reached statistical significance at the age of 12
and 16-weeks, respectively (p < 0.05, one-way ANOVA,
Figure 6A and B). Again, the change of both tau species
Table 1 List of tau species detected and antibody
reagents used in the AlphaLISA immunoassays developed
for this study
Tau Species Biotin-donor Acceptor
Total tau Tau12 HT7
Tau aggregates HT7 HT7
p231 HT7 PHF6
pT202/205 HT7 AT8














nY29 tau HT7 anti-nY29
CSF total tau HT7 BT2
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development of tauopathy (R2 = 0.70, p < 0.0001 for nY29
and R2 = 0.94, p < 0.0001 for ub-tau, Figure 6C and D).
Similar to the various tau species comprising pathological
tau in the brain, there was a large inter-animal variation in
CSF tau as rTg4510 mice age (Figure 7A). However, unlike
the steady accumulation of total tau and various p-tau spe-
cies in brain as rTg4510 mice age (e.g. as illustrated by
PHF6 tau levels in Figure 7B), levels of total tau in CSF of
rTg4510 mice changed in a multi-phasic pattern during
aging. CSF total tau consistently decreased from 6 to 8–12
weeks of age, although the decrease was not statistically sig-
nificant. Subsequently, CSF total tau progressively increased,
with the increase reaching statistical significance at 16 weeks
of age and beyond (one-way ANOVA, p < 0.05). After reach-
ing a peak at 20 weeks of age, CSF total tau then showed a
steady decline that was statistically significantly from 24–32
weeks of age (p < 0.05, one-way ANOVA) (Figure 7B).
When gender difference was assessed, female Tg4510
mice had an overall higher level of total tau (main effect
of sex, F(1,166) = 19.43, p < 0.00010), tau aggregates
(main effect of sex, F(1,170) = 6.59, p < 0.02) and PHF6
tau (main effect of sex, F(1,172) = 18.78, p < 0.0001) as
the mice aged; however, rTg4510 mice of both genders
reached similar peak values at 30–32 weeks of age(Figure 8A-C). Female Tg4150 mice also had higher CSF
total tau levels during aging as compared to male mice
[main effect of sex, F(1,197) = 21.24, p < 0.0001], but
eventually similar levels of CSF total tau were observed
in females and males at ages >24 weeks (Figure 8D).
Discussion
rTg4510 mice express human tau with the P301L muta-
tion and provide many advantages to study tauopathy,
including a rapid onset of NFT formation and a brain
distribution of NFTs mirroring that seen in AD patients.
The development of tauopathy in this model has been
well characterized in several studies [10-12,18]. We re-
port here using an immunoassay platform to analyze dif-
ferent tau species in rTg4510 mouse brain. The higher
throughput of this platform enabled us to study larger
groups of animals to mitigate the large inter-animal vari-
ations in the time course and extent of tauopathy in this
model. The sensitivity and the quantitative nature of
these assays also allowed us to more precisely investigate
the relationships between different features of tauopathy.
One of the characteristic features of NFT pathology
in the brains of AD patients is the accumulation of
hyperphosphorylated tau aggregates [2]. Many of the
serine and threonine residues in tau have been re-
ported to be phosphorylated in the brains of AD patients
[4]. The hyperphosphorylation of tau is associated with a
transition of tau from a predominantly soluble, lower mo-
lecular weight species to a predominantly insoluble, higher
molecular weight species, a transition that is thought to be
intimately associated with the development of tauopathy
and neurodegeneration [2]. Consistent with previous re-
ports [10,19], our data showed that as rTg4510 mice age,
tau progressively transitions from a 55 kD species found
predominantly in the soluble fraction of brain homoge-
nates to a 64 kD species found predominantly in the insol-
uble fraction. Interestingly, some p-tau species are present
in both the soluble and insoluble fractions of rTg4510 brain
homogenates, while other p-tau species are primarily
present in the insoluble fraction. However, both are present
in the insoluble, 64 kD form of tau that is thought to be as-
sociated with the development of tauopathy (Figure 1).
Thus, the 64 kD tau cannot be said to comprise only one
or even a few p-tau species, but rather encompasses the
global phosphorylation of tau at all epitopes studied. These
data also suggest that the accumulation of 64 kD tau in the
insoluble fraction can be used as a surrogate marker to
monitor tauopathy development and that a treatment re-
ducing pathological tau formation should lead to a correla-
tive reduction of all tau species associated with tauopathy.
Although NFT histology is typically first observed at 4–5
months of age, our biochemical analysis points to a steady
accumulation of PHF6 and other pathological forms of tau
starting from the young age of 6–8 weeks, with the
A B 
Figure 2 Age-dependent change of total tau and tau aggregates in the brain insoluble fraction of rTg4510 mice. Brain insoluble
fractions from animals 6–32 weeks of age (n = 18-20 per group) were analyzed using AlphaLISA based immunoassays. A. Total tau measured in
an immunoassay using biotin-Tau12 for capture and HT7-conjugated acceptor beads for detection. Twenty ng of protein from the insoluble
fractions were used per assay. Recombinant tau (Millipore) was used to generate a standard curve for quantification. B. Tau aggregates measured
in an immunoassay using HT7 as both capture and detection antibody. Two hundred ng of protein from the insoluble fractions were used in
each assay. The Y-axis is the relative fluorescence readout from Envision (PerkinElmer). Compared to 8-week old mice, total tau and tau aggregate
changes reached statistical significance after 14-, and 16-weeks of age, respectively (p <0.05, one-way ANOVA).
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weeks. This finding points to the possibility for the effective
use of the rTg4510 model to assess prophylactic treatments
targeting tauopathy at ages as early as 6–8 weeks and for
durations of treatment as short as 8–10 weeks.
In addition to phosphorylation, several additional post-
translational modifications are also associated with patho-
logical tau [4,5]. Like many species of p-tau, several other
post-translationally modified forms of tau increased in
the insoluble fraction of brain homogenates as rTg4510
mice aged, including tau aggregates, ac-tau, ub-tau and
nY29 tau. Acetylated tau also transitioned from a pre-
dominantly soluble 55 kD species to an insoluble 64 kD
species in rTg4510 brain homogenates as the animals
aged (Figure 6A). These data provide the first compre-
hensive characterization of the behavior of these more
recently described post-translationally modified forms
of tau in the rTg4510 mouse model.A B
Figure 3 Age-dependent change of p-tau in the brain insoluble fracti
weeks of age (n = 18-20 per group) were analyzed using AlphaLISA based
phosphorylation (C) were measured using biotin-HT7 for capture and spec
the insoluble fractions were used in each assay. The Y-axis is the relative flu
old mice, PHF6, AT8 and pThr tau changes reached statistical significance a
one-way ANOVA).Our data demonstrated a close correlation between all
the post-translationally modified species of tau examined
in this study (Figures 4, 5 and 6, Additional file 2:
Figure S2), suggesting these modifications are not sep-
arate and unrelated events but may collectively con-
tribute to the disease process. Pathological tau thus
represents a heterogeneous pool of mis-folded proteins
encompassing tau phosphorylated at multiple epitopes
as well as multiple additional post-translationally
modified tau species. These post-translational modifi-
cations may occur more or less simultaneously as tauo-
pathy develops and it is difficult to distinguish which
one(s) (aggregation, phosphorylation, acetylation, etc.)
may be the primary driver of the development of
pathological tau. Further investigation in these areas is
critical to understand the disease mechanism in the
rTg4510 model and assess therapeutics targeting
tauopathy.C 
on of rTg4510 mice. Brain insoluble fractions from animals 6–32
immunoassays. PHF6 tau (A), AT8 tau (B), and pThr global tau
ific p-tau antibodies for detection. Two hundred ng of protein from
orescence readout from Envision (PerkinElmer). Compared to 8-week




Figure 4 Correlation of various tau species in the insoluble fraction of rTg4510 mouse brain. The data in Figures 2 and 3 were analyzed
for correlation with PHF6 tau using Prism 5.0 software. Shown are correlations of PHF6 tau with: A. AT8 tau; B. pThr tau global phosphorylation;
C. tau aggregates; and D. total tau.







Figure 5 Acetylated tau in rTg4510 brain. A. Western blot of acetylated tau probed by ac-280, a polyclonal antibody specific for tau acetylated
at Lys280. B. Age-dependent change of acetylated tau in the soluble and insoluble fractions of rTg4510 mouse brain. Acetylated tau was
measured using 1 μg of protein from the soluble or insoluble fractions of rTg4510 mouse brain with biotin HT7 for capture and a pan
acetyl-lysine antibody for detection. The error bars represent the standard error for each group. The change of ac-tau reached statistical significance at
14-weeks of age as compared to 8-weeks (p < 0.05, one-way ANOVA). C. Correlation of the levels of acetylated tau and PHF6 tau in the insoluble fraction
of rTg4510 mouse brain.
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Figure 6 Age-dependent change of ubiquitination and nitration of tau in the brain insoluble fraction of rTg4510 mice. Post-translational
modifications were measured using AlphaLISA immunoassays with 1 μg of protein from the brain insoluble fraction of rTg4510 mice. A. Age-dependent
change of tau ubiquitination. Ub-tau was detected using biotin HT-7 for capture and an anti-ubiquitin antibody for detection. B. Age-dependent change
of Tyr29 nitration of tau. nY29 tau was detected using biotin HT-7 for capture and an anti-nY29 antibody for detection. C. and D. Correlation of Ub-tau
(C) and nY29 tau (D) with PHF6 tau. Correlation analysis was done using Prism 5.0 software.
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translationally modified forms of tau, although significant,
are not linear. This is likely due to the technical limitation
that we cannot assess assay linearity without a standard
for each tau species. Therefore, the sample loadings in the
analyses were determined by dilution linearity of the
middle-aged samples and thus may not cover the wide
range of tau levels in the different age groups. The lack of
assay standards for each specific tau species also means
we cannot determine the absolute concentration andA B
Figure 7 Age-dependent change of CSF total tau in rTg4510 mice. CS
antibody for capture and antibody BT2 conjugated acceptor beads for dete
(Milipore) was used to generate a standard curve for quantification. A. Age
age-dependent changes in mean brain PHF6 tau levels from Figure 3A (op
bars represent the standard error of the mean.stoichiometry of each species in this pool of pathological
tau. However, this limitation does not impact the conclu-
sion that all post-translational modifications of tau studied
are all temporally associated with the development of
tauopathy.
Elevation of CSF total tau is a characteristic feature of
AD and is being explored as a diagnostic biomarker and
as a biomarker to identify patients in clinical trials of po-
tential AD therapeutics [6]. The elevation of CSF tau
was first hypothesized to be a consequence of neuronalF total tau was measured using an AlphaLISA assay with biotin HT7
ction. One microliter of CSF was used per assay and recombinant tau
-dependent change in CSF total tau in Tg4510 mice. B. Re-plotting of




Figure 8 Gender difference in rTg4510 mice. Data from previous figures were plotted separately for male (open circle) and female (solid circle)
mice. Error bars represent the standard error of the mean. Factorial ANOVAs were used to analyze the brain and CSF tau data for male and
female mice at various ages with sex and age as the between subjects factors. A. Total Tau. Total tau levels were greater in the brains of female
mice compared to males [main effect of sex, F(1,166) = 19.43, p < 0.0001], total tau levels varied as the mice aged and the age-related variation
was different for females compared to males [Sex x Age interaction, F(9,166) = 2.43, p < 0.02] with the males catching up to the females by 24
weeks of age. B. PHF6 Tau. Female mice had higher levels of PHF6 tau compared to males [main effect of Sex, F(1,172) = 18.78, p < 0.0001] and
PHF6 tau levels increased as the mice aged. C. Tau Aggregation. Female mice showed greater tau aggregation than males [main effect of Sex,
F(1,170) = 6.59, p < 0.02], tau aggregation increased and peaked as the mice aged and the age-related variation was different for females
compared to males [Sex x Age interaction, F(9,170) = 2.56, p < 0.009] with the tau aggregation peaking earlier in females than males (24 weeks vs. 28
weeks). D. CSF Total Tau. Female mice had higher CSF total tau levels compared to males [main effect of Sex, F(1,197) = 21.24, p < 0.0001], CSF total tau
levels varied as the mice aged and the difference between females and males varied at different ages [Sex x Age interaction, F(11,197) = 2.31, p < 0.02]
with similar levels being observed in females and males at older ages.
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presence of tau in the CSF of healthy individuals of all
ages. The emerging evidence that tau is released from
normal cells and neurons [20-22], possibly as a mechan-
ism of removing excessive cellular metabolites [23], pro-
vides an alternative hypothesis of the source of CSF tau.
In rTg4510 mice, CSF tau changes in several phases as
the animals age, a temporal pattern that is distinct from
the steady increase of brain tauopathy (Figure 7B). Our
findings are consistent with a previous report [24] and
suggest that CSF tau levels in this model are likely deter-
mined by both normal tau metabolism (e.g. constitutive
secretion by cells) and by processes associated with
pathological tau formation. Further understanding the
nature of age-dependent changes in CSF tau may lead to
important insights into the mechanism of tauopathy
progression and biomarker development for AD therapy.
Although there is a clear trend of pathological tau de-
velopment in Tg4510 mice, the accumulation of patho-
logical tau displays large variations in all parameters
assessed. These variations are consistent with findingsby others and are not due to differential transgene ex-
pression ([24], L. Song and L. Zhang unpublished data).
It has been reported previously that female rTg4510
mice display more robust tau pathology and more severe
deficits in spatial learning and memory tests [25]. Our
data provide further evidence for a gender difference in
that female rTg4510 mice showed significantly more ag-
gressive age-dependent accumulation of pathological tau
in all features we assessed (Figure 8A-D). The underlying
mechanism for the gender difference is not clear but our
observations provide important information for using
this model in terms of gender selection or balance and
group size to give sufficient power for target effect size.
Conclusion
Our data demonstrate that tauopathy in rTg4510 mice de-
velops via accumulation of a pool of pathological tau that
carries multiple post-translational modifications, a process
that can be detected well before the histological detection
of NFTs and is more pronounced in female rTg4510 mice.
Although hyperphosphorylation is the best known
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post-translationally modified forms of tau (e.g. acetylation,
ubiquitination, nitration) that correlate equally well with
formation of pathological tau and also temporally correlate
with formation of hyperphosphorylated tau. Therefore, it is
not clear which of the post-translational modification
events is the proximal cause of pathological tau formation.
Nevertheless, the data suggests that a treatment that re-
duces pathological tau formation should lead to a correla-
tive reduction of all tau species associated with tauopathy.
CSF tau in rTg4510 mice is likely derived from both nor-
mal metabolism and the formation of pathological tau and
exhibits a complex temporal pattern that is distinct from
the progressive increase in pathological tau formation in
the brain. Further understanding of the biological and
pathological processes of CSF tau production remains an
important aspect for future studies given its importance as
a translational biomarker of efficacy and patient selection
for preclinical and clinical testing of potential treatments
targeting tauopathies. In summary, this study provides sev-
eral important insights into the development of tauopathy
in rTg4510 mice and into the use of this model to assess
potential therapeutic treatments targeting tau pathology.
Methods
Reagents
Antibodies used for Western blots and AlphaLISA assays
are listed in Table 2. Ac-280 is a custom rabbit polyclonal
antibody developed against an acetylated tau peptide asTable 2 Antibody reagents used in this study
Antibody Epitope Source
HT7 aa159-163 Thermo Scientific
BT2 aa194-198 Thermo Scientific
Tau12 N-terminus Covance
AT270 pT181 Thermo Scientific
AT180 pT231 Thermo Scientific
AT100 pS212/T214 Thermo Scientific
PHF6 PHF around pT231 Covance
AT8 pS202/T205 Thermo Scientific
PHF13 PHF pT396 Covance




p-Thr pan phosphor-threonine Sigma
Ac-Lys pan acetyl-lysine Cell Signaling
Ac-280 aa264-287 with acetyl-Lys280 Prepared as described
in [13]
Ubiqutin pan ubiquitin Millipore
nY29 nitrated tyrosine 29 Abcamdescribed [14]. The serum was pre-absorbed with an un-
modified tau peptide of the same amino acid sequence
before being affinity purified using the acetylated peptide
(GenScript). The specificity of ac-280 was confirmed by
Western blots showing that this antibody selectively picked
up hyper-acetylated tau when tau was co-transfected with
histone acetyltransferase P300 in HEK293 cells (Additional
file 3: Figure S3).Animals
The rTg4510 mouse line overexpressing the human tau
0N4R isoform carrying the P301L mutation [10] was licensed
from the Mayo Clinic and bred at Taconic in Germantown,
NY. The mice were bred by crossing the hTau responder line
(FVB/N strain) and the tTA activator line (129S6 strain) as
described [10]. All animal procedures are in compliance with
the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use
Committee of Merck Research Laboratories, an AAALAC
accredited institution.
Animals of different ages (gender balanced, n = 18–20
per group with the exception of 12 at 6 weeks of age
and 15 at 20 weeks of age) were euthanized with CO2.
Brain and CSF were collected from each animal. For
CSF collection, mice were euthanized and placed on a
table with the head tilted down 70–80 degrees. The skin
was removed to expose muscles located between the
ears, the caudal part of head and the rostral neck to lo-
cate the cisterna magna. A 27G butterfly needle con-
nected to a 1 ml syringe was used to punch through the
muscle to the cisterna magna and about 10 μL CSF was
collected by slightly pulling the syringe.Preparation of brain fractions
The soluble and insoluble fractions of rTg4510 mouse
brain were prepared based on a previously published
method with some modifications [12]. Briefly, half brains
from rTg4510 or wild-type mice were homogenized using
metal beads with TissueLyzer (Qiagen) in 900 μL prepar-
ation buffer containing 50 mM Tris, pH 8.0, 250 mM
NaCl, 5 mM KCl, 2 mM EDTA, 2 mM EGTA, Phospho-
Safe extraction buffer (EMD/Novagen) plus Complete
EDTA-free Protease Inhibitor Tablet (Roche), PhoStop
Tablet (Roche), 2 μM Trichostatin A (Sigma-Aldrich),
5 mM Nicotinamide (Sigma-Aldrich), and 1 μM PUGNAc
(Sigma-Aldrich). The homogenates were centrifuged at
14,000 g for 15 min to remove the tissue debris. The super-
natants were then centrifuged at 100,000 g for 30 min. The
pellets were re-suspended in the preparation buffer, and
the supernatants and the pellets from the second spin were
defined as the soluble and insoluble fraction, respectively.
Protein concentrations were determined using the BCA
assay kit (Pierce).
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A comprehensive panel of sandwich immunoassays listed
in Table 1 was developed to measure different forms of
tau. In general, analytes were captured by a monoclonal
antibody that was biotinylated and bound to streptavidin
coated donor beads (PerkinElmer). Detection was accom-
plished either by a monoclonal antibody conjugated to the
acceptor beads directly or by a polyclonal antibody in com-
bination with anti-rabbit IgG-conjugated acceptor beads
(PerkinElmer).
Assay reactions (25 μl) were carried out in OptiPlate-
384 microplates (PerkinElmer) that contained 5 μL of
analyte at the specified protein concentration, 10 μL of
biotinylated capture antibody (final concentration 2 nM)
and 10 μL of detection antibody-conjugated acceptor
beads (final concentration 20 μg/mL). After overnight
incubation at 4°C, 25 μL of streptavidin donor beads
were added under subdued light conditions (final con-
centration 40 μg/mL) and the reactions were incubated
at room temperature for 60 min with gentle shaking.
The fluorescent signal was detected on an Envision Plate
Reader at 615 nm (PerkinElmer).Total tau and tau aggregates
Total tau assays were defined as detection of tau using
antibodies recognizing epitopes not affected by phosphor-
ylation. Here we used biotin-Tau 12 with HT7 conjugated
acceptor beads for analyzing brain total tau, and biotin-
HT7 with BT2 conjugated acceptor beads for analyzing
CSF total tau. Recombinant tau (Millipore) was used to
generate a standard curve for quantification. In addition,
biotin-HT7 was also used in combination with HT7 conju-
gated acceptor beads for analyzing aggregated forms of tau.
This assay detects any tau aggregate that is a dimer or
larger, and thus does not distinguish between soluble oligo-
meric and insoluble, higher order aggregates of tau. Formic
acid treatment, which denatures tau aggregates, abolished
the signal in this HT7-HT7 assay (data not shown). The
total tau assay detects both 55 and 64 kD tau species while
the aggregated tau assay preferentially detects the 64 kD
species that is enriched in aggregated forms of tau.Phospho-tau (p-tau)
P-tau species were determined using biotin-HT7 as the
capture antibody and acceptor beads conjugated to
epitope-specific monoclonal antibodies for detection. Glo-
bal phosphorylation was assessed by using biotin-HT7 as
the capture antibody and a pan anti-pThr antibody conju-
gated to acceptor beads for detection. As there is no stand-
ard available for each p-tau and other post-translationally
modified tau species, we cannot determine the absolute
linearity for each assay. The dilution linearity was tested
using the brain lysates of the 16 week old brain samples(data not shown) and the results were used to guide the
amount of protein used in the assays.
Acetylated tau (ac-tau), ubiquitinated tau (ub-tau) and
nitrated tau (nY-tau)
To assess tau acetylation, ubiquitination and nitration dur-
ing aging, biotin-HT7 was used as the capture antibody in
combination with either a pan anti-acetylated lysine mono-
clonal antibody, an anti-ubiquitin antibody or an anti-nY29
tau antibody conjugated to acceptor beads for detection.
Western blot analysis
The soluble or insoluble fractions of brain extracts were
separated on NuPage gels (Invitrogen) and transferred to
a nitrocellulose membrane. The antibody used in each
blot was as specified. The blots were developed using
electrochemiluminescence (ECL) according to the man-
ufacturer’s instruction (Amersham GE HealthCare).
Statistical analysis
The GraphPad Prism program was used for statistical ana-
lysis. Factorial ANOVAs were used to analyze the brain
and CSF tau data for male and female mice at various ages
with sex and age as the between subjects factors.
Additional files
Additional file 1: Figure S1. Age-dependent change of pS262, pS400,
AT180, PHF13, AT100 and pS409 tau in the brain insoluble fraction from
rTg4510 mice. Brain insoluble fractions from animals 6–32 weeks of
age (n = 18-20 per group) were analyzed using AlphaLISA based
immunoassays. pS262 tau (A.), pS400 tau (B.), AT180 (pT231) tau (C),
PHF13 tau (D), AT100 tau (E) and pS409 tau (F) tau were measured using
biotin-HT7 for capture and specific p-tau antibodies for detection. Two
hundred ng of protein from the insoluble fractions were used in each assay.
The Y-axis is the relative fluorescence readout from Envision (PerkinElmer).
Compared to 8-week old mice, the changes of p-tau reached statistical
significance at ages 20, 16, and 20 weeks of age for pS262, pS400 and AT180
(pT231), respectively. PHF13 tau, AT100 tau and pS409 tau were all
significantly elevated at week 16 and 32 as compared to 8-week old mice
(p < 0.01).
Additional file 2: Figure S2. Correlation of various tau species in the
insoluble fraction of rTg4510 mouse brain. The data in Figure 3 and
Additional file 1: Figure S1 were analyzed for correlation with PHF6 tau
using Prism 5.0 software. Shown are correlations of PHF6 tau with: A. pS262
tau; B. pS400 tau; C. AT180 tau; D. PHF13 tau; E. AT100 tau; and F. pS409 tau.
Additional file 3: Figure S3. ac-Tau (K280) antibody reacts specifically
to acetylated tau. HEK293 cells were transfected with vector control
(Mock), human tau (Tau), or co-transfected with human tau and P300
catalytic domain (Tau & P300). At 24 hours post transfection, the cells
were treated with HDAC inhibitors (10 mM sodium butyrate & 1 μM
Trichostatin A, 24 hours) or HAT inhibitor C646 [14] (20 μM, 8 hours) as
indicated. Ten microgram of cell lysate was loaded for Western blotting
to detect total tau with HT-7 monoclonal antibody (1 μg/ml), acetylated
tau with K280 polyclonal antibody (1:1000), and acetylated tubulin with
an ac-tubulin monoclonal antibody (Sigma, 1 μg/ml) as a control.
Abbreviations
AD: Alzheimer’s disease; FTDP-17: Frontotemporal dementia with
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CSF: Cerebrospinal fluid; p-tau: Phosphorylated tau.
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